- Conditions
- Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
- Interventions
- Lumacaftor Plus Ivacaftor Combination, Ivacaftor
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 91
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 88 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Pulmonary Hypertension, Familial Persistent, of the Newborn
- Interventions
- placebo, iv sildenafil
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 0 Days to 4 Days
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Sacramento, California • Washington D.C., District of Columbia + 8 more
- Conditions
- Retinopathy of Prematurity (ROP), Intraventricular Hemorrhage, Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity
- Interventions
- No Intervention
- Other
- Lead sponsor
- Oak Hill Bio Ltd
- Industry
- Eligibility
- 12 Months to 24 Months
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 4
- States / cities
- South Bend, Indiana • Jackson, Mississippi • New Brunswick, New Jersey
- Conditions
- Cystic Fibrosis
- Interventions
- ELX/TEZ/IVA, IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 33
- States / cities
- Tucson, Arizona • Long Beach, California • Palo Alto, California + 28 more
- Conditions
- Pulmonary Hypertension of Newborn
- Interventions
- INOmax
- Drug
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 27 Weeks to 40 Weeks
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 27 more
- Conditions
- Infant, Newborn, Diseases, Cardiovascular Insufficiency
- Interventions
- Hydrocortisone, Placebo
- Drug
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- 34 Weeks and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 14 more
- Conditions
- Infant, Newborn, Hypertension, Pulmonary, Persistent Fetal Circulation Syndrome, Pneumonia, Aspiration, Respiratory Distress Syndrome, Newborn, Respiratory Insufficiency
- Interventions
- Inhaled nitric oxide, Placebo
- Drug
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- Up to 14 Days
- Enrollment
- 235 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 1998
- U.S. locations
- 11
- States / cities
- Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 8 more
- Conditions
- Infant, Newborn, Hypotension, Blood Pressure
- Interventions
- Not listed
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- Up to 72 Hours
- Enrollment
- 820 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more
- Conditions
- Cystic Fibrosis
- Interventions
- ELX/TEZ/IVA, IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 458 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 42 more
- Conditions
- Cystic Fibrosis
- Interventions
- Inhaled mannitol, Placebo Comparator: Arm B - Control
- Drug
- Lead sponsor
- Syntara
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 423 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 36
- States / cities
- Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 32 more
- Conditions
- Cystic Fibrosis
- Interventions
- Not listed
- Lead sponsor
- Steven M Rowe
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 31 more
- Conditions
- Magnetic Resonance Imaging
- Interventions
- Gadobutrol (Gadavist, BAY86-4875)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- Up to 2 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 5
- States / cities
- Savannah, Georgia • Chicago, Illinois • Boston, Massachusetts + 2 more
- Conditions
- Cystic Fibrosis
- Interventions
- Ataluren
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Infant, Newborn, Hypoxia-Ischemia, Brain
- Interventions
- Induced hypothermia, Control
- Device
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- Up to 6 Hours
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2010
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more
- Conditions
- Adenosine Deaminase Deficiency, Severe Combined Immunodeficiency (SCID)
- Interventions
- autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)
- Biological
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- Not listed
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2040
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Cystic Fibrosis
- Interventions
- ivacaftor, Placebo
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Congenital Diaphragmatic Hernia, Pulmonary Hypoplasia
- Interventions
- FETO with GoldBAL2 Balloon and BALTACCIBDPE100 Catheter
- Device
- Lead sponsor
- Holly L Hedrick, MD
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Cerebral Palsy
- Interventions
- Not listed
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- Up to 72 Hours
- Enrollment
- 1,067 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1999 – 2004
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Palo Alto, California • San Diego, California + 14 more
- Conditions
- Anemia, Sickle Cell
- Interventions
- Hydroxyurea
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 2 Years to 7 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 10 more
- Conditions
- Bronchopulmonary Dysplasia
- Interventions
- Massimo Root Monitoring System, ISA-Infrared Sidestream Gas Analyzer
- Device
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 3 Days to 1 Year
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cystic Fibrosis
- Interventions
- ELX/TEZ/IVA, IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 507 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 52
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 47 more
- Conditions
- Hunter Syndrome, Mucopolysaccharidosis II (MPS II)
- Interventions
- Idursulfase
- Biological
- Lead sponsor
- Shire
- Industry
- Eligibility
- 5 Years and older · Male only
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Oakland, California • Denver, Colorado + 13 more
- Conditions
- Ichthyosis
- Interventions
- Ustekinumab
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Placental Transfusion
- Interventions
- Short Delay Cord Clamping, Extended Delay Cord Clamping
- Procedure
- Lead sponsor
- Anup Katheria, M.D.
- Other
- Eligibility
- 37 Weeks to 42 Weeks
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- San Diego, California